ADRIATIC : When face value is enough

Scientific article

English

Published inMed, vol. 5, no. 11, p. 1348-1350

Publication date2024-11-08

Abstract

The ADRIATIC¹ study marks a major advancement in limited-stage small cell lung cancer (LS-SCLC), showing that consolidation therapy with durvalumab after chemoradiation significantly improves overall survival (OS) and progression-free survival (PFS). This establishes durvalumab as the new standard of care for LS-SCLC.

Keywords

Affiliation entities

Citation (ISO format)

ADDEO, Alfredo, LIU, Stephen V. ADRIATIC : When face value is enough. In: Med, 2024, vol. 5, n° 11, p. 1348–1350. doi: 10.1016/j.medj.2024.10.004

Article (Published version)

Identifiers

Journal ISSN2666-6340

44views

0downloads

Creation25/02/2025 09:17:57

First validation20/03/2025 08:15:57

Update20/03/2025 08:15:57

Status update20/03/2025 08:15:57

Last indexation20/03/2025 08:15:58